[PDF][PDF] The unfolded protein response mediator PERK governs myeloid cell-driven immunosuppression in tumors through inhibition of STING signaling

E Mohamed, RA Sierra, J Trillo-Tinoco, Y Cao… - Immunity, 2020 - cell.com
E Mohamed, RA Sierra, J Trillo-Tinoco, Y Cao, P Innamarato, KK Payne, A de Mingo Pulido
Immunity, 2020cell.com
The primary mechanisms supporting immunoregulatory polarization of myeloid cells upon
infiltration into tumors remain largely unexplored. Elucidation of these signals could enable
better strategies to restore protective anti-tumor immunity. Here, we investigated the role of
the intrinsic activation of the PKR-like endoplasmic reticulum (ER) kinase (PERK) in the
immunoinhibitory actions of tumor-associated myeloid-derived suppressor cells (tumor-
MDSCs). PERK signaling increased in tumor-MDSCs, and its deletion transformed MDSCs …
Summary
The primary mechanisms supporting immunoregulatory polarization of myeloid cells upon infiltration into tumors remain largely unexplored. Elucidation of these signals could enable better strategies to restore protective anti-tumor immunity. Here, we investigated the role of the intrinsic activation of the PKR-like endoplasmic reticulum (ER) kinase (PERK) in the immunoinhibitory actions of tumor-associated myeloid-derived suppressor cells (tumor-MDSCs). PERK signaling increased in tumor-MDSCs, and its deletion transformed MDSCs into myeloid cells that activated CD8+ T cell-mediated immunity against cancer. Tumor-MDSCs lacking PERK exhibited disrupted NRF2-driven antioxidant capacity and impaired mitochondrial respiratory homeostasis. Moreover, reduced NRF2 signaling in PERK-deficient MDSCs elicited cytosolic mitochondrial DNA elevation and, consequently, STING-dependent expression of anti-tumor type I interferon. Reactivation of NRF2 signaling, conditional deletion of STING, or blockade of type I interferon receptor I restored the immunoinhibitory potential of PERK-ablated MDSCs. Our findings demonstrate the pivotal role of PERK in tumor-MDSC functionality and unveil strategies to reprogram immunosuppressive myelopoiesis in tumors to boost cancer immunotherapy.
cell.com